DK2924047T3 - Vaccinebærer - Google Patents

Vaccinebærer Download PDF

Info

Publication number
DK2924047T3
DK2924047T3 DK15161237.1T DK15161237T DK2924047T3 DK 2924047 T3 DK2924047 T3 DK 2924047T3 DK 15161237 T DK15161237 T DK 15161237T DK 2924047 T3 DK2924047 T3 DK 2924047T3
Authority
DK
Denmark
Prior art keywords
ala
glu
lys
leu
asp
Prior art date
Application number
DK15161237.1T
Other languages
English (en)
Inventor
Rudolf Valenta
Margarete Focke-Tejkl
Birgit Linhart
Susanne Vrtala
Peter Valent
Renate Reininger
Susanne Spitzauer
Ines Swoboda
Hage Marianne Van
Hans Grönlund
Johanna Tinhofer
Kerstin Westritschnig
Theresia Popow-Kraupp
Original Assignee
Biomay Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomay Ag filed Critical Biomay Ag
Application granted granted Critical
Publication of DK2924047T3 publication Critical patent/DK2924047T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • A61K39/36Allergens from pollen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32711Rhinovirus
    • C12N2770/32734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (10)

1. A Hypoallergent molekyle, der er afledt af Phl p 5 og består af amino-syresekvens GAASNKAFAEGLSGEPKGAAESSSKAALTSK, ADLGYGPAT-PAAPAAGYTPATPAAPAEAAPAGK eller TVATAPEVKYTVFETALKKAI-TAMSEAQKAAK.
2. Hypoallergent fusionsprotein omfattende et hypoallergent molekyle ifølge krav 1 fusioneret på mindst et viruscapsidprotein, hvor det hypoallergene molekyle er fusioneret på N-terminus og/eller C-terminus af det mindst ene viruscapsidprotein.
3. Hypoallergent protein ifølge krav 2, kendetegnet ved, at det mindst ene viruscapsidprotein er afledt fra en human patogen virus.
4. Hypoallergent protein ifølge krav 3, kendetegnet ved, at den humane patogene virus er en virus af familien picornaviridae.
5. Hypoallergent protein ifølge krav 4, kendetegnet ved, at virussen af familien picornaviridae er af arten af rhinovira, fortrinsvis af arten af humane rhino-vira, især human rhinovirus 89 eller 14.
6. Nukleinsyremolekyle, der koder for et hypoallergent molekyle ifølge krav 1 eller et hypoallergent fusionsprotein ifølge et hvilket som helst af kravene 2 til 5.
7. Vektor omfattende et nukleinsyremolekyle ifølge krav 6, hvor vektoren med hensyn til en nukleinsyre, der koder for Phl p5, består af en nukleinsyrese-kvens, der koder for det hypoallergene molekyle bestående af aminosyrese-kvensen defineret i krav 1.
8. Vaccineformulering omfattende et hypoallergent molekyle ifølge krav 1 eller et hypoallergent fusionsprotein ifølge et hvilket som helst af kravene 2 til 5.
9. Formulering ifølge krav 8, kendetegnet ved, at formuleringen yderligere omfatter mindst en adjuvans, et farmaceutisk acceptabelt hjælpestof og/eller konserveringsmiddel.
10. Hypoallergent molekyle ifølge krav 1 eller hypoallergent fusionsprotein ifølge et hvilket som helst af kravene 2 til 5 til anvendelse ved behandling eller forebyggelse af en allergi hos et menneske eller et dyr.
DK15161237.1T 2006-06-09 2007-06-11 Vaccinebærer DK2924047T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0099406A AT503690A1 (de) 2006-06-09 2006-06-09 Hypoallergene moleküle
EP07718492.7A EP2035457B1 (en) 2006-06-09 2007-06-11 Vaccine carrier

Publications (1)

Publication Number Publication Date
DK2924047T3 true DK2924047T3 (da) 2018-12-03

Family

ID=38650124

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15161237.1T DK2924047T3 (da) 2006-06-09 2007-06-11 Vaccinebærer
DK07718492.7T DK2035457T3 (da) 2006-06-09 2007-06-11 Vaccinebærer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07718492.7T DK2035457T3 (da) 2006-06-09 2007-06-11 Vaccinebærer

Country Status (14)

Country Link
US (2) US9296828B2 (da)
EP (2) EP2924047B1 (da)
JP (3) JP5399895B2 (da)
CN (3) CN103319601A (da)
AT (1) AT503690A1 (da)
AU (1) AU2007257308B2 (da)
BR (1) BR122019004393B1 (da)
CA (1) CA2657971C (da)
DK (2) DK2924047T3 (da)
ES (2) ES2541311T3 (da)
PL (1) PL2035457T3 (da)
PT (1) PT2035457E (da)
RU (1) RU2486206C2 (da)
WO (1) WO2007140505A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
EP2444100A3 (en) * 2008-08-15 2012-07-25 Circassia Limited Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
EP2384336B1 (en) * 2008-12-30 2014-03-05 Chua, Kaw Yan A variant of mite allergen and uses thereof
CO6260019A1 (es) 2009-01-30 2011-03-22 Fundacion Universidad Del Norte Metodo y composicion inmunoquimica para la deteccion de alergenos de acaros usando anticuerpos policlonales igy
BRPI1008802A2 (pt) * 2009-02-05 2016-03-08 Circassia Ltd composição, vetor e formulação farmacêutica para o uso na prevenção ou tratamento de alergia a pólen de grama por tolerização, produto, e, método in vitro para determinar se as células t reconhecem uma composição
AU2013202362B2 (en) * 2009-02-05 2015-09-17 Circassia Limited Grass Peptides for Vaccine
EP2316481A1 (en) * 2009-10-30 2011-05-04 Biomay Ag Pharmaceutical composition for the treatment and prevention of a rhinovirus infection
MX343386B (es) 2011-06-09 2016-11-03 Biomay Ag Proteinas de fusion portadoras de peptido como vacunas para alergia.
US9005627B2 (en) * 2011-06-27 2015-04-14 Anergis S.A. Contiguous overlapping peptides for treatment of ragweed pollen allergy
EP2543725A1 (en) * 2011-07-08 2013-01-09 Biomay Ag Polysaccharide lyases
JO3820B1 (ar) * 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
GB201209868D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Alternaria peptides
US9163069B2 (en) 2012-09-20 2015-10-20 Universidad De Cartagena Fusion proteins representing different allergens and a vaccine against allergy to mites
JP2014231500A (ja) * 2013-05-29 2014-12-11 元晴 植原 シラカンバ花粉症の免疫療法に用いるペプチド混合物
US10935554B2 (en) 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
WO2017004561A1 (en) * 2015-07-01 2017-01-05 Alk-Abelló A/S Peptide combinations and uses thereof for treating grass allergy
US11352417B2 (en) 2016-12-22 2022-06-07 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
US11408895B1 (en) 2018-04-09 2022-08-09 Hob Biotech Group Corp., Ltd. Allergen characterization, potent allergen product formulation, comprehensive allergen reagent, and allergy assay
EP3569612A1 (en) * 2018-05-18 2019-11-20 Biomay Ag Treatment and prevention of house dust mite allergies
RU2761431C9 (ru) 2020-10-26 2022-04-18 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Рекомбинантный полипептид на основе аллергена пыльцы березы и аллергена яблока в качестве вакцины от аллергии

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8821077D0 (en) 1988-09-08 1988-10-05 Wellcome Found Peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6019972A (en) * 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
NZ299122A (en) * 1991-10-16 2005-02-25 Immulogic Pharma Corp Detecting and treating allergies using peptides with T-cell stimulating activity
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AT401937B (de) * 1993-04-01 1996-12-27 Biomay Prod & Handel Rekombinantes lieschgras pollen allergen phl p ii
DE69333979T2 (de) * 1993-04-14 2006-12-21 Heska Corp.(n.d.Ges, d.Staates Delaware), Loveland T-zell epitope der hauptallergene von dermatophagoides (hausstaubmilbe)
WO1995028424A1 (en) * 1994-04-14 1995-10-26 Immulogic Pharmaceutical Corporation Pharmaceutical peptide formulations for treatment of dust mite allergy
SE9402089D0 (sv) * 1994-06-14 1994-06-14 Rudolf Valenta Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules, diagnostic and therapeutic uses of said allergens and fragments
US6572859B1 (en) * 1999-10-29 2003-06-03 Pharmacia Diagnostics Ab Non-anaphylactic forms of grass pollen Phl p 6 allergen and their use
US20030166518A1 (en) * 2000-01-13 2003-09-04 Beardslee Thomas A. Method for allergen characterization
US7279306B2 (en) * 2000-07-06 2007-10-09 Georgetown University Stable (fixed) forms of viral capsid proteins, and viral capsid protein fusions, preferably papillomavirus L1 proteins, and uses thereof
ES2209563B1 (es) 2000-07-28 2005-10-01 Universidad Complutense De Madrid Produccion en la levadurapipchia pastoris y sistema de purificacion del alergeno recombinante de olea europaea ole e 1 para uso en diagnosis y tratamiento de alergias.
AU2002223505B2 (en) * 2000-11-16 2006-12-07 Alk-Abello A/S Mutant allergens
EP1221317A1 (en) * 2000-12-28 2002-07-10 SHAN-Beteiligungsgesellschaft m.b.H. Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
CA2477409C (en) 2002-02-27 2015-01-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung Process for the preparation of hypoallergenic major birch pollen allergen rbet v 1
CA2490866A1 (en) 2002-06-26 2004-01-08 Advanced Bionutrition Corporation Viruses and virus-like particles for multiple antigen and target display
KR20050044886A (ko) 2002-07-05 2005-05-13 데니스 르클레르 면역보조 바이러스 입자
DE60301944T2 (de) 2003-01-21 2006-06-01 Biomay Produktions- Und Handels-Aktiengesellschaft Verfahren zur Vorbereitung von hypoallergenen Mosaikproteinen#
GB0308988D0 (en) * 2003-04-17 2003-05-28 Univ Singapore Molecule
ES2434720T3 (es) * 2003-06-04 2013-12-17 Merck Patent Gmbh Derivados de LOL P 5 con alergenicidad reducida y reactividad frente a células T mantenida
US20050053615A1 (en) * 2003-07-16 2005-03-10 Best Elaine A. Variants of mite group 1 allergens for the treatment of house dust mite allergy
DE10351471A1 (de) * 2003-11-04 2005-06-09 Ursula Prof. Dr. Wiedermann-Schmidt Polyvalente Allergievakzine
US20050214321A1 (en) * 2003-12-01 2005-09-29 Dow Global Technologies Inc. Recombinant icosahedral virus like particle production in pseudomonads
US7928290B2 (en) * 2004-02-27 2011-04-19 Dow Agrosciences Llc Viral capsid fusion peptide expressing plant cells
ITRM20040103A1 (it) * 2004-02-27 2004-05-27 Consiglio Nazionale Ricerche Proteine di fusione comprendenti allergeni della famiglia delle ns-ltps, loro usi e composizioni farmaceutiche che le comprendono.
US20060088549A1 (en) * 2004-07-08 2006-04-27 Arnold Gail F Chimeric virus vaccine
DE102004035337A1 (de) * 2004-07-21 2006-03-16 Merck Patent Gmbh Varianten der Gruppe 1-Allergene aus Poaceae mit reduzierter Allergenität und erhaltener T-Zellreaktivität
WO2006032674A1 (en) * 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide
AT501101B1 (de) * 2004-12-02 2008-01-15 Biomay Ag Protein-allergen-derivat
DK1868642T3 (da) * 2005-03-18 2013-06-24 Cytos Biotechnology Ag Katte-allergenfusionsproteiner og anvendelser deraf
DE602006014846D1 (de) * 2005-09-15 2010-07-22 Alk Abello As Verfahren zur quantifizierung von allergenen

Also Published As

Publication number Publication date
PL2035457T3 (pl) 2015-10-30
US20160257722A1 (en) 2016-09-08
DK2035457T3 (da) 2015-06-15
RU2008152045A (ru) 2010-07-20
US9296828B2 (en) 2016-03-29
PT2035457E (pt) 2015-07-28
WO2007140505A2 (en) 2007-12-13
US20090324501A1 (en) 2009-12-31
EP2924047A1 (en) 2015-09-30
CA2657971C (en) 2018-01-23
BR122019004393B1 (pt) 2023-10-17
BRPI0712421A2 (pt) 2012-06-19
WO2007140505A3 (en) 2008-03-20
RU2486206C2 (ru) 2013-06-27
JP2009539354A (ja) 2009-11-19
ES2698525T3 (es) 2019-02-05
JP2014064573A (ja) 2014-04-17
CN101466738A (zh) 2009-06-24
CA2657971A1 (en) 2007-12-13
ES2541311T3 (es) 2015-07-17
AU2007257308A1 (en) 2007-12-13
EP2035457B1 (en) 2015-04-01
JP2014087341A (ja) 2014-05-15
EP2924047B1 (en) 2018-08-22
JP5399895B2 (ja) 2014-01-29
AU2007257308B2 (en) 2013-06-06
CN103319601A (zh) 2013-09-25
AT503690A1 (de) 2007-12-15
CN103319602B (zh) 2016-09-07
CN103319602A (zh) 2013-09-25
EP2035457A2 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
DK2924047T3 (da) Vaccinebærer
US11376320B2 (en) Immunogenic and vaccine compositions against SARS-CoV-2
DK2717910T3 (da) Peptidbærerfusionsproteiner som allergivacciner
TWI620574B (zh) ***合成胜肽緊急疫苗
CN113454102A (zh) 非洲猪瘟疫苗
CN106794236B (zh) A群链球菌疫苗
JP2013520487A (ja) 免疫原性タンパク質および組成物
WO2022003119A1 (en) Cross-reactive coronavirus vaccine
CN109923125B (zh) 免疫原性组合物
US10117923B2 (en) Production of an immunogen using a plant virus
US20210393768A1 (en) Compositions and methods for preventing and treating virus infection
WO2022207645A1 (en) Sars-cov-2 subunit vaccine
RU2689552C2 (ru) Новая иммунотерапевтическая композиция и ее применения
EP2987502B1 (en) Peptide adjuvants
EP4138901A1 (en) Compositions and methods for inducing immune responses against class i fusion protein viruses
TWI605056B (zh) 用於治療艱難梭狀芽孢桿菌(Clostridium difficile)相關疾病之組成物及方法
RU2775621C2 (ru) Иммуногенный пептид против стрептококков группы а
WO2023081861A1 (en) Enhanced expression via autotransporters
AU2014352986A1 (en) Pan pollen immunogens and methods and uses thereof for immune response modulation
AU2013222053B2 (en) Vaccine carrier
CN117957017A (zh) 包含重组重叠肽和天然蛋白质的疫苗制剂
WO2023137522A1 (en) Chimeric polypeptides
AU2023208227A1 (en) Chimeric polypeptides
JP2008504004A (ja) 穀物からの4群主要アレルゲンのdna配列および組換え製剤
BRPI0712421B1 (pt) Proteína de fusão hipoalergênica derivada de phl p 5